A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration
Advanced Solid Tumor
DRUG: Gumarontinib Tablets
DLT(Dose limit toxity), To evaluate the DLT in patients with advanced solid tumor, 35 days|MTD(Max tolerance does), To evaluate the MTD in patients with advanced solid tumor, 35 days|BED(Biological effective dose), To evaluate the BED in patients with advanced solid tumor, 35 days|objective response rate (ORR), To evaluate the ORR in patients with advanced solid tumor in Ib, 8 weeks
This is a phase I study, its purpose to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD)/ biologically effective dose (BED) and the recommended phase II dose (RP2D) of SCC244 monotherapy in patients with advanced MET alterations solid tumors;